EGFR and non-small cell lung carcinoma: In this study, 81 EGFR-mutant advanced NSCLC patients who were confirmed to have acquired T790M mutation were enrolled, and the clinical implications of dynamic plasma cfDNA analysis using a 425-gene capture panel during the third-generation TKI treatment was investigated.